Pharma Business - August 25, 2020
AstraZeneca’s Imfinzi approved in Japan for the treatment of ES-SCLC
Imfinzi has been approved in Japan for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with etoposide plus a choice of platinum chemotherapy (either carboplatin or cisplatin). SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly, despite initial response to chemotherapy. “This approval […]
Pharma Business - August 19, 2020
AstraZeneca’s Imfinzi granted FDA Priority Review
AstraZeneca’s Imfinzi (durvalumab) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for a new four-week, fixed-dose regimen for treatment in the approved indications of non-small cell lung cancer (NSCLC) and bladder cancer. If approved, Imfinzi could be administered intravenously every four weeks at a fixed dose of […]
COVID-19 - August 17, 2020
AstraZeneca concludes agreement with the EC for the supply of COVID-19 vaccine
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of the AZD1222 COVID-19 vaccine. Building on the existing agreement with Europe’s Inclusive Vaccines Alliance spearheaded by Germany, France, Italy and the Netherlands, this new agreement will give all EU member states the option to access the vaccine […]
Pharma Business - August 12, 2020
AstraZeneca’s Breztri Aerosphere approved in the US for the maintenance treatment of COPD
AstraZeneca’s Breztri Aerosphere has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The approval by the US Food and Drug Administration (FDA) was based on positive results from the Phase III ETHOS trial in which Breztri Aerosphere, a triple-combination therapy, showed a statistically significant reduction in […]
Agreement - August 11, 2020
AstraZeneca and Daiichi Sankyo enter collaboration
AstraZeneca has entered into a new global development and commercialization agreement with Daiichi Sankyo Company, for DS-1062, Daiichi Sankyo’s trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for the treatment of multiple tumour types. DS-1062 is currently in development for the treatment of multiple tumours that commonly express the cell-surface […]
Clinical Trials - August 4, 2020
AstraZeneca announces results from Phase III ETHOS trial
Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). Compared with Bevespi Aerosphere (glycopyrronium/formoterol fumarate), Breztri Aerosphere achieved a 24% reduction […]
